Briquilimab
Phase 1Terminated 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Allergic Asthma
Conditions
Allergic Asthma
Trial Timeline
Nov 26, 2024 → Aug 11, 2025
NCT ID
NCT06592768About Briquilimab
Briquilimab is a phase 1 stage product being developed by Jasper Therapeutics for Allergic Asthma. The current trial status is terminated. This product is registered under clinical trial identifier NCT06592768. Target conditions include Allergic Asthma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06736262 | Phase 2 | Active |
| NCT06592768 | Phase 1 | Terminated |
| NCT06353971 | Phase 1/2 | Terminated |
| NCT06162728 | Phase 1/2 | Active |
Competing Products
20 competing products in Allergic Asthma